Uncategorized
Allergan acquires Oculeve
Allergan has successfully completed the acquisition of Oculeve, according to a press release. Under the terms of the agreement, Allergan acquired Oculeve, which is focused on developing treatments for dry eye disease, for an upfront payment of $125 million and commercialization milestone payments related to lead development program OD-01. The agreement includes the acquisition of an additional earlier-stage dry eye device development program, the release said.